Assessment and Diagnosis of HIV-Associated Dementia
Open Access
Abstract
The modern combined antiretroviral treatment (cART) for human immunodeficiency virus (HIV) infection has substantially lowered the incidence of HIV-associated dementia (HAD). The dominant clinical features include deficits in cognitive processing speed, concentration, attention, and memory. As people living with HIV become older, with high rates of comorbidities and concomitant treatments, the prevalence and complexity of cognitive impairment are expected to increase. Currently, the management of HAD and milder forms of HAND is grounded on the best clinical practice, as there is no specific, evidence-based, proven intervention for managing cognitive impairment. The present article acknowledges the multifactorial nature of the cognitive impairments found in HIV patients, outlining the current concepts in the field of HAD. Major areas of interest include neuropsychological testing and neuroimaging to evaluate CNS status, focusing on greater reliability in the exclusion of associated diseases and allowing for earlier diagnosis. Additionally, we considered the evidence for neurological involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the impact of the coronavirus (COVID-19) pandemic, with wider consequences to population health than can be attributed to the virus itself. The indirect effects of COVID-19, including the increased adoption of telehealth, decreased access to community resources, and social isolation, represent a significant health burden, disproportionately affecting older adults with dementia who have limited social networks and increased functional dependence on the community and health system. This synopsis reviews these aspects in greater detail, identifying key gaps and opportunities for researchers and clinicians; we provide an overview of the current concepts in the field of HAD, with suggestions for diagnosing and managing this important neurological complication, which is intended to be applicable across diverse populations, in line with clinical observations, and closely representative of HIV brain pathology.Keywords
This publication has 131 references indexed in Scilit:
- A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorderJournal of NeuroVirology, 2013
- A Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia ScalePLOS ONE, 2013
- Exploring the Utility of the Montreal Cognitive Assessment to Detect HIV-Associated Neurocognitive Disorder: The Challenge and Need for Culturally Valid Screening Tests in South AfricaThe Clinical Neuropsychologist, 2013
- HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsJournal of NeuroVirology, 2010
- Functional Consequences of HIV-Associated Neuropsychological ImpairmentNeuropsychology Review, 2009
- Cognitive Neuropsychology of HIV-Associated Neurocognitive DisordersNeuropsychology Review, 2009
- False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testingJournal of Clinical Virology, 2008
- Variable patterns of neuropsychological performance in HIV-1 infectionJournal of Clinical and Experimental Neuropsychology, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapyJournal of NeuroVirology, 2008